<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="181">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00275912</url>
  </required_header>
  <id_info>
    <org_study_id>CTRI476BRU02</org_study_id>
    <nct_id>NCT00275912</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures</brief_title>
  <official_title>A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to collect additional data regarding the efficacy in reducing the
      frequency of partial seizures, as well as the safety and tolerability, of oxcarbazepine
      monotherapy in children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Epileptic activity at electroencephalography in rest</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Flash light and hyperventilation test with electroencephalography</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of epileptic episodes according to patient's diary</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram analysis for rhythm and conduction</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood test for sodium, hepatic enzymes and blood cells</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety of 24 week's treatment with oxcarbazepine monotherapy in children with partial seizures</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with total and partial control of epilepsy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients requiring additional antiepileptic drugs</measure>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Epilepsy, Partial Seizures</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxcarbazepine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females, 6 months - 17 years of age;

          -  diagnosis of epilepsy, partial seizures;

          -  ineffective or intolerable present therapy with 1 antiepileptic drug, or none of
             previous antiepileptic therapy

        Exclusion Criteria:

          -  progressive lesion of brain revealed by CT/MRI that performed no earlier than 2 years
             prior to screening;

          -  non-epileptic seizures;

          -  drug or alcohol dependence during a year prior to screening;

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Pediatric Clinical Hospital №1 EkaterinburgRegional Pediatric Clinical Hospital №1</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Scientific Research Institute of Pediatrics and Pediatric Surgery</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian State Medical University clinically based on Russian Pediatric Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific-practical centre of children treatment suffering from craniofacial malformation and congenital pathology of nervous system</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Pediatrics Medical Academy</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 7, 2012</lastchanged_date>
  <firstreceived_date>January 11, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsies, Partial</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Oxcarbazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
